SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (7585)6/14/2004 2:58:11 PM
From: tuck  Read Replies (1) of 10280
 
From Forbes:

>>06.14.04, 11:32 AM ET

Morgan Stanley raised estimates on Sepracor (nasdaq: SEPR - news - people ), citing an anticipated January 2005 launch of Estorra, an insomnia treatment. The specialty pharmaceuticals company presented a number of Estorra studies at an Associated Professional Sleep Societies meeting last week. Morgan Stanley said its observations from physician interviews at the conference were that: physicians are looking forward to the Estorra launch; the National Institutes of Health Consensus Committee should focus on potentially removing transient use restriction for insomnia medications at next year's meeting; doctors are still hesitant to prescribe insomnia medications for long-term use; there is a high co-morbidity between insomnia and other disorders such as depression; and insomnia continues to be an under-recognized/under-treated disorder. Morgan Stanley narrowed the 2004 outlook to a loss of $2.34 per share from $2.68, and raised the 2005 estimate to earnings of 5 cents from a loss of 22 cents. "We believe a Type II review of the Estorra NDA and a January 2005 product launch is the most likely scenario," the research firm said. Morgan Stanley rates Sepracor at "equal-weight" with a $50 price target. <<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News